THERAVANCE BIOPHARMA INC
NASDAQ: TBPH (Theravance Biopharma, Inc.)
Kemas kini terakhir: 5 jam lalu17.00
-0.01 (-0.06%)
| Penutupan Terdahulu | 17.01 |
| Buka | 17.01 |
| Jumlah Dagangan | 445,413 |
| Purata Dagangan (3B) | 530,866 |
| Modal Pasaran | 881,080,320 |
| Harga / Pendapatan (P/E TTM) | 7.62 |
| Harga / Pendapatan (P/E Ke hadapan) | 7.91 |
| Harga / Jualan (P/S) | 8.01 |
| Harga / Buku (P/B) | 3.02 |
| Julat 52 Minggu |
| Margin Keuntungan | -89.38% |
| Margin Operasi (TTM) | -93.80% |
| EPS Cair (TTM) | -1.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 29.01% |
| Nisbah Semasa (MRQ) | 4.77 |
| Aliran Tunai Operasi (OCF TTM) | 32.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 4.64 M |
| Pulangan Atas Aset (ROA TTM) | -7.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Theravance Biopharma, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.5 |
| Purata | -0.63 |
|
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.48% |
| % Dimiliki oleh Institusi | 91.75% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SAMAHA ELI | - | 17.01 | -343,661 | -5,857,969 |
| Jumlah Keseluruhan Kuantiti Bersih | -343,661 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -5,857,969 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 17.01 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SAMAHA ELI | 07 Jul 2026 | Jual (-) | 5,564 | 17.01 | 94,644 | |
| SAMAHA ELI | 06 Jul 2026 | Jual (-) | 1,400 | 17.00 | 23,800 | |
| SAMAHA ELI | 01 Jul 2026 | Jual (-) | 37,799 | 16.98 | 641,827 | |
| SAMAHA ELI | 30 Jun 2026 | Jual (-) | 25,027 | 17.00 | 425,459 | |
| SAMAHA ELI | 29 Jun 2026 | Jual (-) | 273,871 | 17.06 | 4,672,239 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |